Cargando…

Chemotherapy for unresectable and recurrent intramedullary glial tumours in children

Adjuvant treatment for intramedullary tumours is based on radiotherapy. The place of chemotherapy in this setting has yet to be determined. Between May 1992 and January 1998, eight children with unresectable or recurrent intramedullary glioma were treated with the BB SFOP protocol (a 16-month chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Doireau, V, Grill, J, Zerah, M, Lellouch-Tubiana, A, Couanet, D, Chastagner, P, Marchal, J C, Grignon, Y, Chouffai, Z, Kalifa, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374296/
https://www.ncbi.nlm.nih.gov/pubmed/10555754
http://dx.doi.org/10.1038/sj.bjc.6690772
_version_ 1782154419746373632
author Doireau, V
Grill, J
Zerah, M
Lellouch-Tubiana, A
Couanet, D
Chastagner, P
Marchal, J C
Grignon, Y
Chouffai, Z
Kalifa, C
author_facet Doireau, V
Grill, J
Zerah, M
Lellouch-Tubiana, A
Couanet, D
Chastagner, P
Marchal, J C
Grignon, Y
Chouffai, Z
Kalifa, C
author_sort Doireau, V
collection PubMed
description Adjuvant treatment for intramedullary tumours is based on radiotherapy. The place of chemotherapy in this setting has yet to be determined. Between May 1992 and January 1998, eight children with unresectable or recurrent intramedullary glioma were treated with the BB SFOP protocol (a 16-month chemotherapy regimen with carboplatin, procarbazine, vincristine, cyclophosphamide, etoposide and cisplatin). Six children had progressive disease following incomplete surgery and two had a post-operative relapse. Three patients had leptomeningeal dissemination at the outset of chemotherapy. Seven of the eight children responded clinically and radiologically, while one remained stable. At the end of the BB SFOP protocol four children were in radiological complete remission. After a median follow-up of 3 years from the beginning of chemotherapy, all the children but one (who died from another cause) are alive. Five patients remain progression-free, without radiotherapy, 59, 55, 40, 35 and 16 months after the beginning of chemotherapy. The efficacy of this chemotherapy in patients with intramedullary glial tumours calls for further trials in this setting, especially in young children and patients with metastases. © 1999 Cancer Research Campaign
format Text
id pubmed-2374296
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23742962009-09-10 Chemotherapy for unresectable and recurrent intramedullary glial tumours in children Doireau, V Grill, J Zerah, M Lellouch-Tubiana, A Couanet, D Chastagner, P Marchal, J C Grignon, Y Chouffai, Z Kalifa, C Br J Cancer Regular Article Adjuvant treatment for intramedullary tumours is based on radiotherapy. The place of chemotherapy in this setting has yet to be determined. Between May 1992 and January 1998, eight children with unresectable or recurrent intramedullary glioma were treated with the BB SFOP protocol (a 16-month chemotherapy regimen with carboplatin, procarbazine, vincristine, cyclophosphamide, etoposide and cisplatin). Six children had progressive disease following incomplete surgery and two had a post-operative relapse. Three patients had leptomeningeal dissemination at the outset of chemotherapy. Seven of the eight children responded clinically and radiologically, while one remained stable. At the end of the BB SFOP protocol four children were in radiological complete remission. After a median follow-up of 3 years from the beginning of chemotherapy, all the children but one (who died from another cause) are alive. Five patients remain progression-free, without radiotherapy, 59, 55, 40, 35 and 16 months after the beginning of chemotherapy. The efficacy of this chemotherapy in patients with intramedullary glial tumours calls for further trials in this setting, especially in young children and patients with metastases. © 1999 Cancer Research Campaign Nature Publishing Group 1999-11 /pmc/articles/PMC2374296/ /pubmed/10555754 http://dx.doi.org/10.1038/sj.bjc.6690772 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Doireau, V
Grill, J
Zerah, M
Lellouch-Tubiana, A
Couanet, D
Chastagner, P
Marchal, J C
Grignon, Y
Chouffai, Z
Kalifa, C
Chemotherapy for unresectable and recurrent intramedullary glial tumours in children
title Chemotherapy for unresectable and recurrent intramedullary glial tumours in children
title_full Chemotherapy for unresectable and recurrent intramedullary glial tumours in children
title_fullStr Chemotherapy for unresectable and recurrent intramedullary glial tumours in children
title_full_unstemmed Chemotherapy for unresectable and recurrent intramedullary glial tumours in children
title_short Chemotherapy for unresectable and recurrent intramedullary glial tumours in children
title_sort chemotherapy for unresectable and recurrent intramedullary glial tumours in children
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374296/
https://www.ncbi.nlm.nih.gov/pubmed/10555754
http://dx.doi.org/10.1038/sj.bjc.6690772
work_keys_str_mv AT doireauv chemotherapyforunresectableandrecurrentintramedullaryglialtumoursinchildren
AT grillj chemotherapyforunresectableandrecurrentintramedullaryglialtumoursinchildren
AT zerahm chemotherapyforunresectableandrecurrentintramedullaryglialtumoursinchildren
AT lellouchtubianaa chemotherapyforunresectableandrecurrentintramedullaryglialtumoursinchildren
AT couanetd chemotherapyforunresectableandrecurrentintramedullaryglialtumoursinchildren
AT chastagnerp chemotherapyforunresectableandrecurrentintramedullaryglialtumoursinchildren
AT marchaljc chemotherapyforunresectableandrecurrentintramedullaryglialtumoursinchildren
AT grignony chemotherapyforunresectableandrecurrentintramedullaryglialtumoursinchildren
AT chouffaiz chemotherapyforunresectableandrecurrentintramedullaryglialtumoursinchildren
AT kalifac chemotherapyforunresectableandrecurrentintramedullaryglialtumoursinchildren